Table 1.
The clinicopathologic characteristics of patients in the training and validation cohorts.
| Parameters | Training cohort (n = 554) | Validation cohort (n = 328) | p Value |
|---|---|---|---|
| Cystatin-C (mg/L) | 1.23 ± 0.51 | 1.20 ± 0.55 | .439 |
| Age (years) | 72.47 ± 12.26 | 72.59 ± 11.92 | .887 |
| HbA1c (%) | 5.60 (5.40–6.00) | 6.00 (5.00–6.00) | .043 |
| Hemoglobin (g/dL) | 13.71 ± 1.52 | 13.88 ± 1.53 | .124 |
| Blood urea nitrogen (mmol/L) | 6.78 (5.00–8.57) | 7.00 (5.00–9.00) | .972 |
| Bicarbonate (mmol/L) | 25.00 (24.00–27.00) | 25.00 (24.00–27.00) | .839 |
| Phosphorus (mmol/L) | 1.22 ± 0.18 | 1.05 ± 0.23 | <.001 |
| Uric acid (µmol/L) | 374.70 (315.20–434.20) | 369.00 (309.00–440.00) | .977 |
| Potassium (mmol/L) | 4.15 ± 0.43 | 4.19 ± 0.51 | .288 |
| UACR (mg/g) | 10.48 (5.62–33.00) | 10.00 (5.00–29.00) | .514 |
| C-reactive protein (mg/dL) | 0.26 (0.13–0.60) | 0.00 (0.00–1.00) | <.001 |
| Homocysteine (umol/L) | 13.66 ± 5.12 | 13.80 ± 5.56 | .692 |
| eGFR (mL/min per 1.73 m2) | 51.05 (43.62–55.91) | 52.50 (44.00–56.00) | .274 |
| Gender (n/%) | .495 | ||
| Women | 247 (44.58%) | 154 (46.95%) | |
| Man | 307 (55.42%) | 174 (53.05%) | |
| Diabetes (n/%) | .529 | ||
| No | 410 (74.01%) | 249 (75.91%) | |
| Yes | 144 (25.99%) | 79 (24.09%) | |
| Hypertension (n/%) | .502 | ||
| No | 182 (32.85%) | 115 (35.06%) | |
| Yes | 372 (67.15%) | 213 (64.94%) | |
| Anemia (n/%) | .48 | ||
| No | 463 (83.57%) | 280 (85.37%) | |
| Yes | 91 (16.43%) | 48 (14.63%) | |
| Death (n/%) | .769 | ||
| No | 237 (42.78%) | 137 (41.77%) | |
| Yes | 317 (57.22%) | 191 (58.23%) |
UACR: urinary albumin-to-creatinine ratio; eGFR: estimated glomerular filtration rate.